These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24976972)

  • 1. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial.
    DeGregorio M; Soe L; Wolf M
    J Thorac Dis; 2014 Jun; 6(6):571-3. PubMed ID: 24976972
    [No Abstract]   [Full Text] [Related]  

  • 2. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
    Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu TE; Bosquée L; Trigo JM; Spira A; Tremblay L; Nyman J; Ramlau R; Wickart-Johansson G; Ellis P; Gladkov O; Pereira JR; Eberhardt WE; Helwig C; Schröder A; Shepherd FA;
    Lancet Oncol; 2014 Jan; 15(1):59-68. PubMed ID: 24331154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
    Katakami N; Hida T; Nokihara H; Imamura F; Sakai H; Atagi S; Nishio M; Kashii T; Satouchi M; Helwig C; Watanabe M; Tamura T
    Lung Cancer; 2017 Mar; 105():23-30. PubMed ID: 28236981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant MUC vaccination with tecemotide after resection of colorectal liver metastases: a randomized, double-blind, placebo-controlled, multicenter AIO phase II trial (LICC).
    Schimanski CC; Kasper S; Hegewisch-Becker S; Schröder J; Overkamp F; Kullmann F; Bechstein WO; Vöhringer M; Öllinger R; Lordick F; Heinemann V; Geißler M; Schulz-Abelius A; Bernhard H; Schön MR; Greil R; Galle P; Lang H; Schmidtmann I; Moehler M
    Oncoimmunology; 2020 Aug; 9(1):1806680. PubMed ID: 32923171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy.
    Kao CJ; Wurz GT; Schröder A; Wolf M; Degregorio MW
    Oncoimmunology; 2013 Oct; 2(10):e26285. PubMed ID: 24498545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-BLP25: a peptide vaccine strategy in non small cell lung cancer.
    Sangha R; Butts C
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4652-4. PubMed ID: 17671159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study.
    Rossmann E; Österborg A; Löfvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schröder A; Mellstedt H
    Hum Vaccin Immunother; 2014; 10(11):3394-408. PubMed ID: 25483677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial.
    Schimanski CC; Möhler M; Schön M; van Cutsem E; Greil R; Bechstein WO; Hegewisch-Becker S; von Wichert G; Vöhringer M; Heike M; Heinemann V; Peeters M; Kanzler S; Kasper S; Overkamp F; Schröder J; Seehofer D; Kullmann F; Linz B; Schmidtmann I; Smith-Machnow V; Gockel I; Lang H; Galle PR
    BMC Cancer; 2012 Apr; 12():144. PubMed ID: 22494623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).
    Singer CF; Pfeiler G; Hubalek M; Bartsch R; Stöger H; Pichler A; Petru E; Bjelic-Radisic V; Greil R; Rudas M; Maria Tea MK; Wette V; Petzer AL; Sevelda P; Egle D; Dubsky PC; Filipits M; Fitzal F; Exner R; Jakesz R; Balic M; Tinchon C; Bago-Horvath Z; Frantal S; Gnant M;
    Eur J Cancer; 2020 Jun; 132():43-52. PubMed ID: 32325419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of immunotherapy in stage III nonsmall cell lung cancer.
    Wrona A
    Curr Opin Oncol; 2019 Jan; 31(1):18-23. PubMed ID: 30489337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial.
    Butts C; Maksymiuk A; Goss G; Soulières D; Marshall E; Cormier Y; Ellis PM; Price A; Sawhney R; Beier F; Falk M; Murray N
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1337-42. PubMed ID: 21744082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
    Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
    J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
    Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
    Mayadev J; Nunes AT; Li M; Marcovitz M; Lanasa MC; Monk BJ
    Int J Gynecol Cancer; 2020 Jul; 30(7):1065-1070. PubMed ID: 32447296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.
    Hui R; Özgüroğlu M; Villegas A; Daniel D; Vicente D; Murakami S; Yokoi T; Chiappori A; Lee KH; de Wit M; Cho BC; Gray JE; Rydén A; Viviers L; Poole L; Zhang Y; Dennis PA; Antonia SJ
    Lancet Oncol; 2019 Dec; 20(12):1670-1680. PubMed ID: 31601496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BLP-25 liposomal vaccine: a promising potential therapy in non-small-cell lung cancer.
    Powell E; Chow LQ
    Expert Rev Respir Med; 2008 Feb; 2(1):37-45. PubMed ID: 20477220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in locally-advanced non-small cell lung cancer: releasing the brakes on consolidation?
    Berman AT; Simone CB
    Transl Lung Cancer Res; 2016 Feb; 5(1):138-42. PubMed ID: 26958509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized phase II study of palifermin for reducing dysphagia in patients receiving concurrent chemoradiotherapy for locally advanced unresectable non-small cell lung cancer.
    Schuette W; Krzakowski MJ; Massuti B; Otterson GA; Lizambri R; Wei H; Berger DP; Chen Y
    J Thorac Oncol; 2012 Jan; 7(1):157-64. PubMed ID: 22011667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
    Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.